


Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments



Edited by
Tuan Anh Nguyen
Bhupendra G. Prajapati
Devesh U. Kapoor



Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments

This page intentionally left blank

Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments

Edited by

Tuan Anh Nguyen

Institute for Tropical Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam

Bhupendra G. Prajapati

Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India

Devesh U. Kapoor

Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, India



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Books and Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorised representative, Elsevier B.V., at productsafety@elsevier.com.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-443-44579-8

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Megan Ball
Acquisitions Editor: Linda Buschman
Editorial Project Manager: Shreya Jain
Production Project Manager: Aishwarya R
Cover Designer: Bakyalakshmi S.

Typeset by MPS Limited, Chennai, India



Dedication

**Dedicated to the memory of those who lost their lives to the
side effects of nanovaccines and nanomedicines**

This page intentionally left blank

Contents

List of contributors	xix	1.9 Conclusion	12
		Acknowledgments	13
		Conflict of Interest	13
		References	13
Part 1		2. Introduction to nanomedicine in cancer treatments	
Fundamentals		<i>Komal, Pratyush Porel, Sonam M. Gandhi and Devesh U. Kapoor</i>	
1. Introduction to nanovaccines		2.1 Introduction	19
<i>Neelakanta Sarvashiva Kiran, Chandrashekar Yashaswini, Ankita Chatterjee, Suhaskumar Patel and Bhupendra G. Prajapati</i>		2.1.1 Overview of cancer and conventional therapies	19
1.1 Introduction	3	2.1.2 Limitations of traditional cancer treatments	19
1.2 Basics of nanotechnology in vaccinology	4	2.1.3 Emergence of nanomedicine in oncology	20
1.3 Mechanisms of action of nanovaccines	5	2.2 Fundamentals of nanomedicine	20
1.3.1 Antigen presentation and immune activation	5	2.2.1 Definition and scope	20
1.3.2 Targeting antigen-presenting cells (APCs)	6	2.2.2 Types of nanomaterials used in medicine	20
1.3.3 Controlled release of antigens and adjuvants	6	2.2.3 Physicochemical properties relevant to cancer therapy	21
1.3.4 Role in both humoral and cellular immunity	6	2.3 Nanocarriers for cancer therapy	22
1.4 Platforms and types of nanovaccines	7	2.3.1 Liposomes	22
1.4.1 Lipid-based nanovaccines	7	2.3.2 Polymeric nanoparticles	22
1.4.2 Polymeric nanovaccines	7	2.3.3 Dendrimers	22
1.4.3 Inorganic nanovaccines	7	2.3.4 Metallic and magnetic nanoparticles	24
1.4.4 Protein-based nanoparticles and virus-like particles (VLPs)	8	2.3.5 Carbon-based nanomaterials	24
1.4.5 Hybrids and biomimetic platforms	8	2.4 Mechanisms of nanomedicine in cancer treatment	24
1.4.6 Comparative design and translational considerations	8	2.4.1 Passive targeting: enhanced permeability and retention (EPR) effect	25
1.5 Advantages of nanovaccines over conventional vaccines	8	2.4.2 Active targeting	25
1.6 Applications of nanovaccines	9	2.4.3 Stimuli-responsive and smart delivery systems	25
1.7 Safety, toxicity, and regulatory considerations	10	2.5 Therapeutic applications	26
1.7.1 Biocompatibility and potential nanotoxicity issues	11	2.5.1 Drug delivery-controlled release	26
1.7.2 Biodistribution and clearance	11	2.5.2 Gene therapy	26
1.7.3 Regulatory hurdles and standardization challenges	11	2.5.3 Photothermal, photodynamic therapy	26
1.8 Future perspectives and challenges	11	2.5.4 Therapeutic with combined diagnosis and treatment	26

2.6	Safety, toxicity, and regulatory considerations	26	4.2	Nanocarriers used in nanomedicine	48
2.6.1	Nanotoxicology and biocompatibility	26	4.2.1	Carbon-based nanomaterials	48
2.6.2	Regulatory guidelines and ethical concerns	27	4.2.2	Inorganic nanoparticles	49
2.7	Future perspectives and challenges	27	4.2.3	Organic nanoparticles	51
2.7.1	Personalized nanomedicine	27	4.3	Advantages of nanoparticles	53
2.7.2	Integration with artificial intelligence and imaging	27	4.3.1	Interaction of nanomedicines with cellular signaling pathways	53
2.7.3	Overcoming drug resistance with nanotechnology	28	4.3.2	Hedgehog signaling pathway	54
2.8	Conclusion	28	4.3.3	Notch signaling pathway	54
	References	28	4.3.4	TGF- β signaling pathway	54
			4.3.5	Clinical applications of nanomedicine	54
			4.3.6	Applications of nanomedicines in diagnostics	55
3.	Sensors for cancer detection		4.4	Potential side effects and toxicity of nanomedicines	55
	<i>Nandani Jayaswal, Shriyansh Srivastava, Rakesh Sahu and Mohd. Tariq</i>		4.4.1	Cellular disruption	55
3.1	Introduction	33	4.4.2	Immunological responses	55
3.2	Types of nanosensors for cancer detection	34	4.4.3	Genotoxicity	55
3.2.1	Optical nanosensors	34	4.4.4	Oxidative stress	55
3.2.2	Electrochemical nanosensors	34	4.4.5	Biodistribution and chronic toxicity	56
3.2.3	Magnetic nanosensors	35	4.5	Strategies for minimizing adverse effects	56
3.2.4	Nanomechanical sensors	35	4.5.1	Dynamic monitoring and imaging integration	56
3.2.5	Biosensors	35	4.5.2	Surface engineering mastery	56
3.3	Mechanisms of nanosensor action	36	4.5.3	Intelligent drug delivery revolution	56
3.3.1	Surface plasmon resonance	36	4.5.4	Harmonizing immunomodulation	56
3.3.2	Quantum dots	36	4.5.5	Enhanced clearance choreography and biodegradability opus	56
3.3.3	Nanowires and nanotubes	36	4.5.6	Simulated protection with in silico predictive proficiency	56
3.3.4	Fluorescence resonance energy transfer	37	4.6	Challenges for nanomedicine	57
3.4	Applications in cancer detection	37	4.6.1	Biological challenges	57
3.4.1	Early cancer detection	38	4.6.2	Scalable manufacturing	57
3.4.2	Tumor biomarker detection	38	4.6.3	Safety evaluation	57
3.4.3	Detection of circulating tumor cells	38	4.6.4	Regulatory challenges	58
3.4.4	Monitoring treatment response	39	4.7	Conclusions and future perspectives	58
3.4.5	Noninvasive detection methods	39		References	58
3.5	Clinical implementation and case studies	39	5.	Current perspectives of nanovaccines and nanomedicines in cancer treatment	
3.5.1	Current clinical trials	39		<i>Ainy Butt, Azka Noor and Fakhar ud Din</i>	
3.5.2	Case studies	42	5.1	Background	63
3.6	Challenges and limitations	43	5.2	Advance treatment and techniques	64
3.7	Future perspectives	43	5.2.1	Nanomedicines	64
3.8	Conclusion	43	5.2.2	Nanovaccines	68
	References	44	5.3	Challenges and future perspective	73
4.	Current perspectives of nanomedicines in cancer treatment		5.4	Conclusions	75
	<i>Nazim Hussain, Hafsa, Rimsha Haqqi, Iqra Arif, Masooma Farrukh and Ayesha Munawar</i>			References	75
4.1	Introduction	47			

Part 2

Advantage and application of nanovaccine and nanomedicine

6. Advantage of cancer nanomedicine

Sara A. Saied, Mohamed T. Selim and Salem S. Salem

6.1 Introduction	81
6.2 Evolution of cancer nanomedicine	81
6.3 Mechanism of action of nanoparticle-mediated drug delivery	82
6.3.1 Passive action	82
6.3.2 Active action	83
6.4 Types of nanocarriers	83
6.4.1 Liposomes	83
6.4.2 Inorganic nanocarriers	86
6.4.3 Polymeric nanoparticles	87
6.4.4 Biological nanocarriers	88
6.5 Application of nanomedicine in cancer therapy	89
6.5.1 Surgery	89
6.5.2 Chemotherapy	89
6.5.3 Augmenting radiotherapy	89
6.5.4 Immunotherapy	90
6.5.5 Photothermal therapy	90
6.5.6 Gene therapy	90
6.5.7 Diagnosis and imaging	90
6.6 Conclusion	91
References	91

7. Advantages of targeted nanomedicine in cancer treatment

Shashi Kiran Misra and Kamla Pathak

7.1 Introduction	95
7.2 Approaches for enhancing targeted medications	95
7.3 Targeted nanomedications for cancers	97
7.3.1 Targeted medications for treatment of glioma and brain cancer	98
7.3.2 Targeted medications for treatment of breast and ovarian cancer	99
7.3.3 Targeted medications for treatment of ovarian cancer	99
7.3.4 Targeted medications for treatment of colon cancer	99
7.4 Targeted nanomedications for autoimmune disorders	101
7.4.1 Targeted medication for treatment of Rheumatoid arthritis	104
7.4.2 Targeted medication of systemic lupus erythematosus and Crohn's disease	104

7.4.3 Targeted medication of Parkinson's disease and autoimmune hepatitis	104
7.4.4 Targeted medication for the treatment of ulcerative colitis	105
7.5 Targeted nanomedications for infectious diseases	105
7.5.1 Targeted medication for treatment of HIV/AIDS	106
7.5.2 Targeted medications for treatment of hepatitis C virus	108
7.5.3 Targeted medications for management of Influenza	108
7.5.4 Targeted medications for treatment of human papillomavirus and Ebola	108
7.6 Challenges with targeted nanomedications	109
7.7 Conclusion	109
References	109

8. Current perspectives of nanovaccines in cancer treatment

Nazim Hussain, Muhammad Luqman Qadir, Samreen Arshad, Amna Saeed, Rowell Maryam, Ayesha Munawar, Masooma Farrukh and Amir Rafeeq

8.1 Introduction	115
8.2 Components of cancer nanovaccines	116
8.2.1 Antigens	116
8.2.2 Adjuvants	117
8.2.3 Nanocarriers	117
8.3 Types of nanovaccines	119
8.3.1 RNA-based nanovaccines	119
8.3.2 Neoantigen nanovaccines	119
8.3.3 Artificial antigen-presenting cell nanovaccines	120
8.3.4 STING agonist-based nanovaccines	120
8.4 Mechanisms of action	121
8.5 Combination therapies with other cancer treatments	122
8.6 Exploring the effectiveness of nanovaccines: clinical examples	122
8.6.1 Cervical carcinoma	122
8.6.2 Colorectal cancer	122
8.6.3 Melanoma	124
8.6.4 Breast carcinoma	124
8.6.5 Lymphoma	124
8.6.6 Human papillomavirus tumor model	125
8.6.7 Lewis's lung cancer	126
8.7 Limitations and challenges	127
8.8 Future directions and developments	127
8.9 Conclusion	128
References	128

9. Nanovaccines and nanomedicines in cancer treatment: current landscape

Joydeep Bhattacharyya and Trishna Bal

9.1 Introduction	133
9.2 Nanomedicine in cancer treatment: current landscape	134
9.2.1 Types of nanomedicines used in oncology	134
9.2.2 Mechanism of action	135
9.2.3 Approved nanomedicines and clinical trials in cancer	136
9.3 Nanovaccines in cancer immunotherapy: current trends	137
9.3.1 Types of nanovaccines	137
9.3.2 Mechanisms of immune modulation	139
9.3.3 Notable examples and clinical developments	139
9.4 Synergistic approaches: combining nanomedicines and nanovaccines	140
9.4.1 Nanocarriers for codelivery of antigens and chemotherapeutics	140
9.4.2 Immuno-nanomedicine platforms	141
9.4.3 Examples of combination strategies in research and clinical translation	141
9.5 Personalize nanomedicine and nanovaccines in oncology	142
9.5.1 Biomarker-driven nanoformulation strategies	142
9.5.2 Role of genomics, proteomics, and AI	142
9.5.3 mRNA nanovaccines and neoantigen targeting	142
9.5.4 Challenges in personalizing delivery systems	143
9.6 Challenges in clinical translation and regulatory considerations	143
9.7 Case studies and current clinical pipeline	144
9.8 Current trends and future directions	144
9.9 Conclusion	145
References	145

Part 3

The other side of nanovaccine and nanomedicine

10. Side effects and toxicity of nanovaccine in cancer treatment

Sharoen Yu Ming Lim

Abbreviations	151
---------------	-----

10.1 Introduction	152
10.2 Mechanisms of action of nanovaccines	153
10.3 Types of toxicity of cancer nanovaccine	153
10.4 Immunogenicity and autoimmune reactions	155
10.5 Organ-specific toxicities	155
10.6 Factors influencing nanovaccine toxicity	157
10.7 Types of nanoparticles and their associated toxicities in cancer nanovaccines	158
10.7.1 Nucleic acid-based platforms (DNA/RNA)	158
10.7.2 Antigen-based nanovaccines	158
10.7.3 Tumor-derived extracellular vesicles	158
10.7.4 Lipid-based nanoparticles and liposomes	158
10.7.5 Polymeric nanoparticles	158
10.7.6 Inorganic nanoparticles	159
10.7.7 Viral and DNA nanoparticles	159
10.8 Combination therapies and clinical validation	159
10.9 Progress, challenges, and future directions	159
10.10 Conclusion	160
References	161

11. Side effect and toxicity of nanomedicine in cancer treatment

Zakir Ali, Ibtihal Fatima, Sunia Azhar and Fakhar ud Din

11.1 Nanomedicines	165
11.1.1 Brief overview of side effect and toxicity differences	165
11.2 Emergence of nanomedicine in cancer treatment	165
11.3 Diagnosis of cancer with nanomedicine	167
11.3.1 Molecular imaging using nanoparticles	167
11.4 Types of nanomedicine induced toxicity	167
11.4.1 Anticancer drug-induced toxicity	167
11.4.2 Nanocarrier associated toxicity	169
11.4.3 Types of nanocarriers used in cancer therapy	170
11.5 Organ specific toxicities	173
11.5.1 Hematological toxicity	173

11.5.2	Gastrointestinal toxicity	173	12.2.3	Nanomedicine strategies for traversing the blood–brain barrier	197
11.5.3	Oral toxicity	174	12.3	Nanomedicines in brain cancer: modalities and mechanisms	198
11.5.4	Hair follicle toxicity	174	12.3.1	Common nanoparticle types in neuro-oncology	198
11.5.5	Nervous system toxicity	175	12.3.2	Mechanisms of action on NPs in brain cancer applications	200
11.5.6	Local toxicity	175	12.4	Mechanisms of neurotoxicity in nanomedicine treatment of brain cancer	202
11.5.7	Hepatic toxicity	175	12.4.1	Cellular and molecular mechanisms of nanoparticle-induced toxicity	202
11.5.8	Renal toxicity	176	12.4.2	Maintaining a balance between therapeutic and toxic effects	203
11.5.9	Urinary tract toxicity	176	12.4.3	Specific regions of the brain vulnerable to nanoparticle exposure	203
11.5.10	Pulmonary toxicity	176	12.5	Evidence from preclinical and clinical studies of nanomedicine in brain cancer	204
11.5.11	Cardiac toxicity	176	12.5.1	In vitro neurotoxicity models	205
11.5.12	Gonadal toxicity	177	12.5.2	In vivo animal models	205
11.6	Mechanism of nanomedicine induced toxicity	177	12.5.3	Clinical data	206
11.6.1	Reactive oxygen species and oxidative stress	177	12.5.4	Limitations in current data	206
11.6.2	Inflammatory mechanism	177	12.6	Risk factors and modulators of neurotoxicity in nanomedicine strategies toward brain cancer	206
11.6.3	Interaction with cellular membranes	178	12.6.1	Physicochemical attributes of nanoparticles	207
11.6.4	Autophagy dysregulation	180	12.6.2	Route of administration	207
11.6.5	Genotoxicity and cell signaling interference	181	12.6.3	Influence of the tumor microenvironment	208
11.7	Physicochemical factors affecting toxicity of nanocarriers	181	12.6.4	Patient-specific factors	208
11.7.1	Particle size of nanoparticles	181	12.7	Strategies to mitigate nanomedicine-associated neurotoxicity	209
11.7.2	Shape of nanoparticles	182	12.7.1	Engineering safer nanoparticles	209
11.7.3	Aggregation	182	12.7.2	Temporal control of drug release	209
11.7.4	Zeta potential	183	12.7.3	Co-delivery of neuroprotective agents	209
11.7.5	Composition	183	12.7.4	Monitoring and biomarkers of neurotoxicity	209
11.7.6	Crystallinity	183	12.8	Ethical and translational considerations of nanomedicines toward brain cancer	210
11.7.7	Surface chemistry	183	12.8.1	Informed consent and patient risk in first-in-human trials	210
11.8	In vitro toxicity assessment methods	184	12.8.2	Long-term neurocognitive effects and quality of life	210
11.8.1	Cell viability assays	184			
11.8.2	Apoptosis and necrosis assay	184			
11.8.3	Oxidative stress assays	185			
11.9	In vivo toxicity assessment methods	185			
11.10	Future perspectives	186			
11.11	Conclusion	187			
References		187			
12.	Crossing the barrier, crossing the line: neurotoxicity of nanomedicines in brain cancer therapy				
	<i>Keith D. Rochfort</i>				
12.1	Introduction	195			
12.2	The blood–brain barrier: a therapeutic frontier	196			
12.2.1	The blood–brain barrier	196			
12.2.2	Blood–brain barrier disruption in brain tumor pathophysiology	197			

12.8.3	Balancing therapeutic urgency with neurotoxicity risks	211	14.3.2	Risks of human exposure to metal/metal oxide nanoparticles	249
12.9	Future directions of nanomedicines for brain cancer	211	14.4	Conclusions	250
12.9.1	Emerging technologies - smarter nanoparticles	211	References	250	
12.9.2	Improved models for preclinical investigations	211	15. Nanotoxicity, safety assessment, regulatory aspects, and clinical trial of nanovaccines/nanomedicine		
12.9.3	Precision nanomedicine	211	<i>Himakshi Baruah, Bhriгу Kumar Das, Tapash Chakraborty, Ankita Kashyap and Anupam Sarma</i>		
12.9.4	Integration of neuro-oncology and nanotoxicology research	212	15.1	Introduction	253
12.10	Conclusion	212	15.2	Benefits and limitations of nanovaccines and nanomedicine	254
References	212		15.3	Stability of nanovaccines and nanomedicine	255
13. Side effects and toxicity of nanoparticles in cancer treatment			15.3.1	Problems related to stability	255
<i>Duygu Aydemir and Nuriye Nuray Ulusu</i>			15.3.2	Factors affecting stability	257
13.1	Introduction	233	15.3.3	Atmospheric conditions for stable formulation	258
13.2	Classification, structural characteristics, and physicochemical properties of nanoparticles	235	15.4	Classification of nanovaccines and nanomedicine	259
13.3	Bioavailability and toxicity of nanoparticles in cancer treatment	236	15.4.1	Natural nanovaccines and nanomedicine	259
13.4	Nanoparticle-induced metabolic alterations involved in the nanotoxicity	237	15.4.2	Synthetic nanomedicine and nanovaccine	260
13.4.1	Inflammation and pyroptosis	237	15.5	Safety assessment of nanovaccines and nanomedicine	262
13.4.2	Immunotoxicity	238	15.5.1	In vitro test	263
13.4.3	Oxidative stress	238	15.5.2	In vivo test	265
13.4.4	Ferroptosis and off-target complications in cancer treatment	238	15.6	Toxicity or nanotoxicity of nanovaccines and nanomedicine	265
13.5	Conclusion	239	15.6.1	Metabolomics-based evaluation of nanoparticle-induced cytotoxicity: in vitro study	266
References	240		15.6.2	In vivo evaluation of nanoparticle toxicity	268
14. Toxicity of metal oxide nanoparticles in nanomedicine—mechanisms and implications			15.7	Challenges in the safety assessment	270
<i>Maricica Stoica, Dimitrie Stoica, Tuan Anh Nguyen, Arun Mittal, Oana Pricopoaia and Claudia Veronica Ungureanu</i>			15.8	Regulatory aspects of nanovaccines and nanomedicine	270
14.1	Introduction	243	15.9	Clinical trial study of nanoparticles and nanovaccines	271
14.2	Metal oxide nanoparticles and their applications in nanomedicine	244	15.10	Patents on nanomedicines and nanovaccines	272
14.2.1	Diagnostics	244	15.11	Conclusion	272
14.2.2	Therapeutics	245	References	275	
14.2.3	Drug delivery	246	16. Nanotoxicity and nano-genotoxicity in cancer care		
14.2.4	Antimicrobial applications	246	<i>Andreza M. Ribeiro, Thais H.S. Flores-Sahaguns, José Vargas, Fabio Furtado, Filipa Mascarenhas-Melo and Ana Figueiras</i>		
14.3	Mechanisms of toxicity and implications	248			
14.3.1	Generation of reactive oxygen species and oxidative stress in normal cells	248			

16.1	Introduction	281	17.5	Organ toxicity of nanoparticles	298
16.2	Nanotechnology in cancer therapy	282	17.5.1	Toxicological effect on liver	298
16.3	Mechanisms of nanotoxicity in cancer care	282	17.5.2	Toxicological effect on spleen	298
16.4	Nano-genotoxicity: DNA damage and repair mechanisms	282	17.5.3	Toxicological effect on lung	299
16.5	Influence of nanoparticle physicochemical properties	283	17.6	Conclusion	299
16.5.1	Size and surface area	283	References	299	
16.5.2	Surface characteristics	283			
16.5.3	Stability of the nanoparticles	283			
16.5.4	Impurities	284			
16.5.5	Routes of exposure	284			
16.6	Oxidative stress and inflammatory responses induced by nanomaterials	284			
16.7	Assessment methods: in vitro and in vivo models	284			
16.8	Comparative analysis of different nanomaterials in cancer therapy	289			
16.9	Mitigation strategies for nanotoxicity in nanomedicine	291			
16.9.1	Surface modification by coating	291			
16.9.2	Functionalization of the nanoparticles for the desired therapeutic target	291			
16.9.3	Inhibition of scavenger receptors	291			
16.10	Regulatory and safety considerations for clinical applications	291			
16.11	Future perspectives: designing safer nanoparticles	291			
	Acknowledgments	292			
	Conflicts of Interest	292			
	Declaration of generative AI in scientific writing	292			
	References	292			
17.	Toxicity evaluation and management for nanoparticles in the cancer therapy		18.	Nanoparticle toxicity in cancer nanomedicine	
	<i>Zahra Esmaeili, Ali Karbalaeei Mahdi and Mahdi Adabi</i>			<i>Karthik Mangu and Chandraiah Godugu</i>	
17.1	Introduction	295	Abbreviations	303	
17.2	Particle size, shape, and surface chemistry	295	18.1	Introduction	304
17.2.1	Particle size	295	18.2	Fundamentals of nanoparticle toxicity	305
17.2.2	Particle shape	295	18.3	Mechanisms of nanoparticle-induced toxicity	306
17.2.3	Surface coating	296	18.3.1	Oxidative stress and reactive oxygen species generation	307
17.3	Dose and administration route	296	18.3.2	Inflammation and immune system dysregulation	307
17.3.1	Dose	296	18.3.3	Genotoxicity and DNA damage	308
17.3.2	Administration routes	296	18.3.4	Mitochondrial dysfunction and apoptosis	309
17.4	General mechanism of nanoparticle toxicity	298	18.3.5	Protein corona formation and altered bioidentity	309
			18.4	Organ-specific toxicity in cancer nanomedicine	309
			18.4.1	Hepatotoxicity	310
			18.4.2	Nephrotoxicity	310
			18.4.3	Pulmonary toxicity	310
			18.4.4	Neurotoxicity and blood-brain barrier penetration	311
			18.4.5	Cardiotoxicity and hematological effects	312
			18.5	Influence of nanoparticle composition and design	312
			18.5.1	Metal and metal oxide nanoparticles	312
			18.5.2	Polymer and lipid-based nanoparticles	313
			18.5.3	Carbon-based nanostructures	313
			18.5.4	Hybrid and multifunctional nanostructures	313
			18.6	Factors modulating nanotoxicity in cancer patients	313
			18.6.1	Dose, size, shape, and surface charge	313
			18.6.2	Tumor microenvironment and immune status	314
			18.6.3	Route of administration and bioaccumulation	314
			18.6.4	Interindividual variability and genetic susceptibility	314

18.7 In vitro and in vivo toxicity assessment models	314	19.2 Materials and methods	329
18.7.1 2D and 3D cell cultures for nanotoxicology	315	19.2.1 Raw materials	329
18.7.2 Animal models for preclinical safety studies	315	19.2.2 Nanoformulation methods	329
18.7.3 Omics-based and high-content screening approaches	315	19.2.3 Characterization techniques	335
18.8 Regulatory landscape and safety guidelines	315	19.2.4 Manufacturing equipment and scale-up strategies	337
18.8.1 Regulatory perspectives from Food and Drug Administration, European Medicines Agency, and Organization for Economic Co-operation and Development	316	19.2.5 Quality control and regulatory considerations	339
18.8.2 Gaps in standardized toxicological testing	316	19.3 Formal analysis and investigation, validation, calculation, and expression of results	339
18.8.3 Risk assessment frameworks for nanomedicine	316	19.3.1 Data from preclinical/clinical studies or manufacturing trials	339
18.9 Strategies to mitigate nanoparticle toxicity	317	19.3.2 Stability and shelf-life studies	340
18.9.1 Surface modification and biocompatible coatings	317	19.3.3 Validation of manufacturing processes	340
18.9.2 Targeted delivery and stimuli-responsive release	317	19.3.4 Calculations	341
18.9.3 Dose optimization and personalized nanomedicine	317	19.3.5 Expression of results	342
18.9.4 Use of in silico modeling and artificial intelligence-based predictions	317	19.4 Discussion and evaluation	342
18.10 Emerging technologies and future perspectives	318	19.4.1 Interpretation of experimental and manufacturing data	342
18.10.1 Biomimetic and intelligent nanoparticles	318	19.4.2 Challenges in manufacturing	342
18.10.2 Organ-on-a-chip and humanized models	318	19.4.3 Benchmarking with existing products	344
18.10.3 Integration of multiomics and systems toxicology	318	19.4.4 Innovations and technological advancements	344
18.11 Conclusion	318	19.4.5 Future directions and research gaps	346
References	319	19.5 Conclusions	346
		References	346
		20. Ethics in nanomedicine and nanovaccine for cancer treatment	
		<i>Darshana S. Morankar, Heenatbegum A. Vohra and Navnath Hatvate</i>	
		20.1 Introduction	355
		20.1.1 Nanomedicine and nanovaccines	355
		20.1.2 Need for ethics and regulations	355
		20.1.3 Scope and purpose of the ethical discussion	355
		20.2 Overview of nanotechnology in cancer therapy	356
		20.2.1 Types of nanomedicine in oncology	356
		20.2.2 Role of nanovaccines in immunotherapy	357
		20.2.3 Examples of current and emerging applications in oncology	357
		20.3 Ethical principles in the biomedical context	357

Part 4 Challenge and perspectives

19. Nanomedicines and nanovaccines manufacturing

Binapani Mahaling, Namrata Baruah, Pranathi Manthripragada and Aumreetam Dinabandhu

19.1 Introduction	327
--------------------------	-----

20.4	Ethical concerns in nanomedicine for cancer	359	21.6	Gene editing	378
20.4.1	Safety and toxicity	359	21.7	Government regulation	379
20.4.2	Informed consent	359	21.8	Conclusion	379
20.4.3	Privacy and data security	359	References		380
20.4.4	Equity and access	360			
20.4.5	Regulatory and approval challenges	360	22. Ethics and regulations in nanomedicines and nanovaccines		
20.4.6	Ethical oversight in research trials	361	<i>Mohammad Hossain and Md. Abu Bin Hasan Susan</i>		
20.5	Ethical issues in nanovaccines for cancer	361	22.1	Introduction	383
20.5.1	Immune system modulation	361	22.2	Nanovaccines	384
20.5.2	Clinical trial ethics	362	22.3	Supremacy of nanovaccines	385
20.5.3	Distribution fairness	362	22.3.1	Enhanced permeability within lymphatic tissues	385
20.6	Regulatory and policy frameworks	363	22.3.2	Precision transport of antigens and adjuvants	385
20.6.1	Overview of existing guidelines	363	22.3.3	Integrated transport of multiple bioactive components	385
20.6.2	Need for nano-specific ethical guidelines	364	22.3.4	Boosted adaptive immunity	385
20.6.3	Characterization and biodistribution	364	22.3.5	Endosome release	385
20.6.4	Role of interdisciplinary oversight committees	365	22.4	Limitations in real-world therapeutic adoption	386
20.7	Case studies	365	22.5	Ethical considerations in scientific innovation and technological advancement	387
20.7.1	Case study 1: COVID-19 vaccine	365	22.6	Ethical principles in clinical practice and biomedical implementation	387
20.7.2	Case study 2: BIND-014 Phase I trial in cancer therapy	366	22.7	Ethical frameworks for decision-makers	389
20.8	Future ethical challenges and recommendations	366	22.7.1	The cost-benefit assessment	389
20.8.1	Use of artificial intelligence and nanorobotics in oncology	366	22.7.2	The principle of precaution	389
20.8.2	Personalization vs privacy	366	22.8	The function of the ethics consultant and the responsibilities of the ethics committee	389
20.8.3	Global governance and transnational research ethics	367	22.9	Justice, beneficence, nonmaleficence, and autonomy in vaccine ethics	390
20.9	Conclusion	367	22.10	Foresight evaluation of ethical challenges in nanomedicine	391
References		368	22.10.1	Foundational assumptions of the analysis	391
			22.10.2	Early-stage ethical concerns	392
21. Ethics in cancer nanomedicine			22.10.3	Mid-range ethical concerns	393
<i>Patel Kshama, Zulueta Jared and Pathak Yashwant V.</i>			22.10.4	Projected ethical issues in the long run	394
21.1	Introduction	373	22.11	Regulatory measures concerning nanomaterials	394
21.1.1	Nanotechnology	373	22.11.1	The necessity for regulatory oversight in nanomedicine	394
21.1.2	Ethics in nanomedicine	373	22.11.2	Barriers to effective regulation of nanomedicines	395
21.2	Informed consent	373	22.11.3	Nanomedicines with regulatory approval	395
21.2.1	History of informed consent	374			
21.2.2	Informed consent in nanomedicine	374			
21.3	Confidentiality and privacy	375			
21.3.1	Microchips in humans	375			
21.4	Environmental considerations	376			
21.5	Cost of nanomedicine	377			

22.11.4 Global regulatory plans for nanomedical applications	396	24.3.5 Expression of results	427
22.12 Regulatory prospects for nanomedicines	396	24.4 Discussion and evaluation	428
22.13 Conclusions	397	24.4.1 Interpretation of safety data	428
Conflict of interest	397	24.4.2 Comparative evaluation across nanocarrier systems	428
Acknowledgment	397	24.4.3 Key challenges in safety assessment	429
References	397	24.4.4 Gaps in current methodologies	429
		24.4.5 Strategies for risk mitigation	429
		24.4.6 Material selection and surface modification	429
23. Regulating nanomedicine: challenges and opportunities		24.5 Conclusions	430
<i>Wilson Engelmann and Raquel von Hohendorff</i>		24.5.1 Summary of safety assessment approaches	430
23.1 Introduction	401	24.5.2 Critical considerations for preclinical and clinical translation	430
23.1.1 Background	401	24.5.3 Future trends	430
23.1.2 Problem statement	401	24.5.4 Concluding remarks	431
23.1.3 Literature review	401	Acknowledgments	431
23.2 Method description and procedure	406	References	431
23.3 Discussion and evaluation	407		
23.4 Conclusion	408		
Acknowledgments	408		
References	408		
		25. Manufacturing nanomedicines and nanovaccines: challenges and issues	
24. Safety assessment for nanomedicines and nanovaccines		<i>Mitra Mosharraf and Rajiv Nayar</i>	
<i>Binapani Mahaling, Namrata Baruah, Pranathi Manthripragada and Aumreetam Dinabandhu</i>		25.1 Introduction	443
24.1 Introduction	411	25.2 Lipid-based nanomedicines and nanovaccines	443
24.2 Materials and methods	412	25.2.1 Liposomes	443
24.2.1 Materials for safety testing	412	25.2.2 Lipid nanoparticles	446
24.2.2 Toxicological assessment methods	417	25.2.3 Manufacturing process for m-RNA-lipid nanoparticles	448
24.2.3 Biodistribution and pharmacokinetics	423	25.2.4 Sterile filtration	451
24.2.4 Immunotoxicity testing	424	25.2.5 Fill-finish process	451
24.2.5 Analytical tools and imaging techniques	426	25.2.6 Final drug product characterization and release	451
24.3 Formal analysis and investigation, validation, calculation, and expression of results	426	25.2.7 Critical process parameters, specification limits, and testing	451
24.3.1 Data analysis from toxicological studies	426	25.2.8 A few challenges for large-scale manufacturing	451
24.3.2 Dose-response relationships and thresholds	427	25.2.9 Lyophilization as an approach to improve room-temperature stability	452
24.3.3 Statistical validation and reproducibility	427	25.3 Virus-like particles as a platform technology for cancer nanovaccines	452
24.3.4 Calculation of safety margins and no observable adverse effect level	427	25.4 Other forms of cancer nanomedicines/nanovaccines	453
		25.5 Conclusions	453
		References	454

26. Future perspectives of nanovaccines and nanomedicines

Masoud Pourrahim

26.1 Introduction	457
26.2 Emerging developments and innovations	457
26.2.1 Comparative evaluation	457
26.2.2 Description of processes	458
26.3 Scientific and clinical gaps	460

26.3.1 Comparative evaluation	460
26.3.2 Description of the challenges	462
26.4 Ethics and regulation	463
26.4.1 Comparative evaluation	463
26.4.2 Description of ethical challenges	465
26.4.3 Regulation	466
References	467

Index	471
-------	-----

This page intentionally left blank

List of contributors

- Mahdi Adabi** Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Zakir Ali** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Iqra Arif** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Samreen Arshad** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Duygu Aydemir** Department of Pediatric Basic Sciences, Division of Medical Genetics, Institute of Child Health, Istanbul University, Istanbul, Türkiye
- Sunia Azhar** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Trishna Bal** Biomaterial and Biomedical Research Lab, Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, India
- Himakshi Baruah** Department of Pharmaceutics, Advanced Drug Delivery Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, Assam, India
- Namrata Baruah** Emory National Primate Research Center, Emory University, Atlanta, GA, United States
- Joydeep Bhattacharyya** Biomaterial and Biomedical Research Lab, Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, India
- Ainy Butt** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Tapash Chakraborty** Department of Pharmaceutics, Advanced Drug Delivery Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, Assam, India
- Ankita Chatterjee** Department of Biotechnology, School of Applied Sciences, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India; Center for Molecular Biology and Biotechnology, REVA Research Center, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India
- Fakhar ud Din** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Aumreetam Dinabandhu** Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
- Wilson Engelmann** Law School, University of Vale do Rio dos Sinos - UNISINOS, São Leopoldo, Rio Grande do Sul, Brazil
- Zahra Esmaeili** Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Masooma Farrukh** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Ibtihal Fatima** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Ana Figueiras** Univ Coimbra, Department of Pharmaceutical Technology, Faculty of Pharmacy, Azinhaga de Santa Comba, Coimbra, Portugal; REQUIMTE/LAQV, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Thais H.S. Flores-Sahaguns** Department of Mechanical Engineering, University of Federal of Paraná (UFPR), Curitiba, Paraná, Brazil
- Fabio Furtado** Department of Mechanical Engineering, University of Federal of Paraná (UFPR), Curitiba, Paraná, Brazil
- Sonam M. Gandhi** S.S. Agrawal Institute of Pharmacy, Navsari, Gujarat, India
- Chandraiah Godugu** Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India

- Hafsa** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Rimsha Haqqi** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Navnath Hatvate** Institute of Chemical Technology, Marathwada Campus, Jalna, Maharashtra, India
- Mohammad Hossain** Department of Chemistry, Bangladesh University of Engineering and Technology (BUET), Dhaka, Bangladesh
- Nazim Hussain** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Zulueta Jared** Lake Erie College of Osteopathic Medicine, College of Medicine, Bradenton, FL, United States
- Nandani Jayaswal** Faculty of Pharmaceutical Sciences, Mahayogi Gorakhnath University Gorakhpur, Gorakhpur, Uttar Pradesh, India
- Devesh U. Kapoor** Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, India
- Ali Karbalaeei Mahdi** Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Ankita Kashyap** Department of Pharmaceutical Chemistry, Institute of Pharmacy, Assam Medical College, Dibrugarh, Assam, India
- Neelakanta Sarvashiva Kiran** Department of Biotechnology, School of Applied Sciences, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India; Center for Molecular Biology and Biotechnology, REVA Research Center, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India
- Komal** Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
- Patel Kshama** Lake Erie College of Osteopathic Medicine, College of Medicine, Bradenton, FL, United States
- Bhriugu Kumar Das** Department of Pharmacology, Pharmacology and Toxicology Research Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, Assam, India
- Sharoen Yu Ming Lim** Universiti Malaysia Sarawak (UNIMAS), Kota Samarahan, Sarawak, Malaysia
- Binapani Mahaling** Schepens Eye Research Institute, Harvard Medical School, Boston, MA, United States
- Karthik Mangu** Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India
- Pranathi Manthripragada** Process Development, Vertex Pharmaceuticals, Boston, MA, United States
- Rowell Maryam** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Filipa Mascarenhas-Melo** Higher School of Health, Polytechnic University of Guarda, Rua da Cadeia, Guarda, Portugal; BRIDGES - Biotechnology Research, Innovation and Design for Health Products, Polytechnic University of Guarda, Guarda, Portugal
- Shashi Kiran Misra** School of Pharmaceutical Sciences, CSJM University Kanpur, Kanpur, Uttar Pradesh, India
- Arun Mittal** Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India
- Darshana S. Morankar** Institute of Chemical Technology, Marathwada Campus, Jalna, Maharashtra, India
- Mitra Mosharraf** HTD Biosystems Inc., Pleasanton, CA, United States; Engimata Inc., Pleasanton, CA, United States
- Ayesha Munawar** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Rajiv Nayar** HTD Biosystems Inc., Pleasanton, CA, United States; Engimata Inc., Pleasanton, CA, United States
- Tuan Anh Nguyen** Institute for Tropical Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam
- Azka Noor** Department of Pharmacy, Nanomedicine Research Group, Quaid-i-Azam University Islamabad, Islamabad, Pakistan
- Suhaskumar Patel** Formulation Research and Development, Amneal Pharmaceutical, Piscataway, NJ, United States
- Kamla Pathak** Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences, Etawah, Uttar Pradesh, India
- Pathak Yashwant V.** College of Pharmacy, University of South Florida, Tampa, FL, United States
- Pratyush Porel** Bharat Technology, Uluberia, Howrah, West Bengal, India
- Masoud Pourrahim** Raya Faravar Fartak Company, International Qazvin University, Qazvin, Iran

- Bhupendra G. Prajapati** Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India
- Oana Pricopoia** “Dunărea de Jos” University of Galați, Romania
- Muhammad Luqman Qadir** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Amir Rafeeq** Department of Allied Health Sciences, King Edward Medical University, Lahore, Punjab, Pakistan
- Andreza M. Ribeiro** Post-graduation Program in Department of Engineering and Material Sciences (PIPE), University of Federal of Paraná (UFPR), Curitiba, Paraná, Brazil; Univ Coimbra, Department of Pharmaceutical Technology, Faculty of Pharmacy, Azinhaga de Santa Comba, Coimbra, Portugal
- Keith D. Rochfort** School of Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland; DCU Life Sciences Institute, Dublin City University, Glasnevin, Dublin, Ireland
- Amna Saeed** Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan
- Rakesh Sahu** School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
- Sara A. Saied** Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt
- Salem S. Salem** Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Nasr, Cairo, Egypt
- Anupam Sarma** Department of Pharmaceutics, Advanced Drug Delivery Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, Assam, India
- Mohamed T. Selim** Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Nasr, Cairo, Egypt
- Shriyansh Srivastava** Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
- Dimitrie Stoica** “Dunărea de Jos” University of Galați, Romania
- Maricica Stoica** “Dunărea de Jos” University of Galați, Romania
- Md. Abu Bin Hasan Susan** Department of Chemistry, University of Dhaka, Dhaka, Bangladesh; Dhaka University Nanotechnology Center (DUNC), University of Dhaka, Dhaka, Bangladesh
- Mohd. Tariq** Department of Academics, Sumandeep Vidyapeeth, Deemed to be University, Vadodara, Gujarat, India; Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, India
- Nuriye Nuray Ulusu** Department of Medical Biochemistry, School of Medicine, Koc University, Sariyer, Istanbul, Türkiye; Koc University Research Center for Translational Medicine (KUTTAM), Sariyer, Istanbul, Türkiye
- Claudia Veronica Ungureanu** “Dunărea de Jos” University of Galați, Romania
- José Vargas** Department of Mechanical Engineering, University of Federal of Paraná (UFPR), Curitiba, Paraná, Brazil
- Heenatbegum A. Vohra** Institute of Chemical Technology, Marathwada Campus, Jalna, Maharashtra, India
- Raquel von Hohendorff** Law School, University of Vale do Rio dos Sinos - UNISINOS, São Leopoldo, Rio Grande do Sul, Brazil
- Chandrashekar Yashaswini** Department of Biotechnology, School of Applied Sciences, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India; Center for Molecular Biology and Biotechnology, REVA Research Center, REVA University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bengaluru, Karnataka, India

This page intentionally left blank

Part 1

Fundamentals

This page intentionally left blank

Chapter 10

Side effects and toxicity of nanovaccine in cancer treatment

Sharoen Yu Ming Lim

Universiti Malaysia Sarawak (UNIMAS), Kota Samarahan, Sarawak, Malaysia

Abbreviations

AIE	Aggregation-Induced Emission
ALNP	Aluminum Nanoparticles
AI	Artificial Intelligence
APCs	Antigen-Presenting Cells
CARPA	Complement Activation-Related Pseudoallergy
CD4⁺	Cluster of Differentiation 4 Positive
CD8⁺	Cluster of Differentiation 8 Positive
CNS	Central Nervous System
CpG	Cytosine–Phosphate–Guanine
CRS	Cytokine Release Syndrome
CTLs	Cytotoxic T Lymphocytes
DCs	Dendritic Cells
EVs	Extracellular Vesicles
GMP	Good Manufacturing Practice
ICIs	Immune Checkpoint Inhibitors
IFN-γ	Interferon Gamma
IL-6	Interleukin-6
IL-10	Interleukin-10
IV	Intravenous
LNPs	Lipid Nanoparticles
mRNA	Messenger Ribonucleic Acid
MHC	Major Histocompatibility Complex
MPLA	Monophosphoryl Lipid A
NCT	National Clinical Trial
PD-1	Programmed Death-1
PD-L1	Programmed Death-Ligand 1
PEG	Polyethylene Glycol
PLGA	Poly(lactic-co-glycolic acid)
PRRs	Pattern Recognition Receptors
RNA	Ribonucleic Acid
ROS	Reactive Oxygen Species
siRNA	Small Interfering Ribonucleic Acid
TLR	Toll-like Receptor
TME	Tumor Microenvironment
TNF-α	Tumor Necrosis Factor-alpha
tEVs	Tumor-Derived Extracellular Vesicles
Tregs	Regulatory T Cells
TSAs	Tumor-Specific Antigens
WHO	World Health Organization

10.1 Introduction

Nanovaccines represent a cutting-edge approach in cancer immunotherapy, utilizing nanoscale materials to deliver antigens and immunomodulatory agents directly to the immune system. By leveraging nanotechnology, these vaccines enhance the specificity, stability, and delivery of therapeutic agents, thereby improving their efficacy against malignancies. Unlike conventional vaccines, nanovaccines can be engineered to overcome the immunosuppressive tumor microenvironment (TME), stimulate robust immune responses, and achieve targeted delivery with minimal systemic exposure. Globally, cancer remains a leading cause of death, accounting for approximately 10 million deaths in 2020, nearly one in six deaths worldwide [1]. The most common cancers include lung, breast, colorectal, prostate, and stomach cancers. Despite advances in treatment, many patients still face poor prognoses due to late diagnosis and treatment resistance. For example, lipid nanoparticles (LNPs) have been successfully employed to deliver mRNA encoding tumor antigens in KRAS-mutant nonsmall cell lung cancer (NSCLC). In a Phase I trial (NCT03639714), an mRNA nanovaccine targeting melanoma-associated antigens demonstrated enhanced intratumoral CD8⁺ T-cell infiltration and a favorable safety profile, with mild local inflammation reported [2].

Cancer cells employ sophisticated strategies to evade immune detection, including immunoediting, a process in which the immune system selectively eliminates highly immunogenic tumor cells while permitting the survival of less detectable variants. This results in a more evasive and heterogeneous TME, where immune resistance mechanisms predominate. Solid tumors such as melanoma and NSCLC frequently overexpress PD-L1, a protein that binds to T-cell receptors and inhibits their cytotoxic function. High mutational burdens further contribute to resistance against immune checkpoint blockade therapies. Tumors also secrete immunosuppressive cytokines like TGF- β and IL-10 and recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which dampen immune responses. Additionally, downregulation of tumor-specific antigens (TSAs) and major histocompatibility complex (MHC) molecules impairs T-cell recognition, facilitating immune evasion. This immune complexity underscores the delicate balance nanovaccines must maintain. While their multifaceted compositions are designed to enhance antigen presentation and immune memory, the inclusion of potent adjuvants and nanocarriers increases the risk of hypersensitivity, cross-reactivity, or unintended immune activation, especially in immunocompromised patients.

In response, scientists are developing novel nanovaccines targeting personalized tumor antigens derived from tumor-specific extracellular vesicles (EVs), aiming to enhance antigen-specific immune responses while minimizing inflammation-related adverse effects [3]. According to the American Cancer Society (2024), the 5-year survival rate for advanced cancers has improved significantly with the advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs). Clinical data show that patients receiving ICIs achieve a median overall survival of 34.8 months, compared to 15.7 months with traditional chemotherapy [4]. However, these advancements also introduce safety concerns, as combining immune checkpoint blockade with nanovaccines may overstimulate nonspecific T cells and lead to serious systemic reactions, including cytokine storms. Nanovaccines co-delivering tumor antigens and TLR agonists such as CpG have been shown to induce significant systemic cytokine responses, including elevated levels of IL-6 and TNF- α within 24 hours of administration [5].

Nanovaccines protect encapsulated antigens from degradation and facilitate their uptake by antigen-presenting cells (APCs), resulting in sustained immune activation. Their ability to co-deliver multiple antigens and adjuvants enhances polyfunctional T-cell responses and offers personalized therapy using patient-specific neoantigens. However, this complexity introduces variability in biological interactions, potentially causing unpredictable toxicity profiles. For instance immune modulators incorporated to overcome TMEs may provoke off-target immune stimulation and systemic inflammation. The development of personalized nanovaccines requires accurate antigen identification through integration of biotechnologies and computational tools [6]. Approaches such as coating nanoparticles with cancer cell membranes offer high specificity but present manufacturing challenges. Nanovaccine production currently faces instability, batch-to-batch variability, and high costs. Moreover, the use of biodegradable and biocompatible nanomaterials must be balanced against the need for structural stability and targeted delivery.

As of 2025, numerous clinical trials are investigating nanovaccine candidates for various cancers, though most remain in Phase I or II due to ongoing challenges related to safety, scalability, and regulatory approval [7]. Adverse effects such as cytokine storms, hepatotoxicity, and off-target immune activation have been observed, particularly in formulations containing potent adjuvants or poorly degradable materials. Advanced analytical platforms, including single-cell RNA sequencing and high-resolution mass cytometry, are increasingly used to dissect immune responses and identify early toxicity signals. The long-term safety of nanovaccines remains uncertain, emphasizing the need for robust toxicological profiling and standardized regulatory frameworks. To ensure clinical translation, future strategies must focus on safety-by-design principles, predictive in silico modeling, and ethical testing approaches that account for patient heterogeneity.

10.2 Mechanisms of action of nanovaccines

Nanovaccines constitute an emerging class of immunotherapeutics that utilize nanotechnology to elicit potent, targeted immune responses against cancer. Unlike traditional cancer vaccines, which often suffer from rapid antigen degradation, poor lymphatic uptake, and limited immunogenicity, nanovaccines offer enhanced delivery efficiency, antigen stability, and immune system activation [8]. By integrating TSAs or patient-specific neoantigens with nanoscale delivery platforms [9,10], nanovaccines facilitate targeted immune engagement and robust cytotoxic responses capable of overcoming the complex immunosuppressive TME [11]. Nanovaccines can be precisely delivered to target tissues and cells using specialized nanocarriers and nanoplatforms, enhancing therapeutic efficacy, prolonging antitumor immune responses, and reducing off-target side effects [12].

Nanovaccines possess several unique advantages over traditional vaccine modalities. Their nanoscale size (10–100 nm) optimizes lymph node targeting and cellular uptake [13]. Moreover, nanocarriers can provide sustained antigen release and co-deliver multiple components, antigens, adjuvants, checkpoint inhibitors, or RNA interference agents in a single formulation [14]. This multimodal capability enables simultaneous immune activation and modulation of the TME, making it possible to induce strong immune responses even in immunologically “cold” tumors [15]. By facilitating precise control over antigen presentation, co-stimulatory signaling, and immune modulation, nanovaccines generate a polyfunctional and durable T-cell repertoire. This is critical for targeting heterogeneous tumor cell populations and establishing long-term immunological memory to prevent recurrence [16].

The immune activation process initiated by nanovaccines is multifaceted. Typically, antigens are encapsulated within or attached to nanoparticles composed of lipid-based, polymeric, or inorganic materials [17]. These carriers protect antigens from enzymatic degradation and promote their targeted delivery to APCs, particularly dendritic cells (DCs). Upon administration, nanoparticles drain into the lymphatic system and accumulate in lymph nodes, key sites for immune priming [18]. Once internalized by DCs through endocytosis, nanovaccine components undergo processing, and antigens are presented on MHC class I and II molecules to naive T cells [19]. Co-delivered immunostimulatory adjuvants, such as Toll-like receptor (TLR) agonists (e.g., cytosine-phosphate-guanine (CpG), polyinosinic: polycytidylic acid (poly I:C), or monophosphoryl lipid A (MPLA)), enhance DC maturation and support effector T cell generation [20]. Some nanovaccine formulations are engineered to disrupt endosomal membranes, allowing antigen escape into the cytosol and favoring cross-presentation via MHC class I, crucial for eliciting cytotoxic CD8⁺ T cell responses [21]. The mechanism by which nanovaccines stimulate antitumor immunity involves targeted delivery to APCs, enhanced antigen processing, and activation of T cell responses within lymphoid tissues (Fig. 10.1). This multistep process enables efficient priming of cytotoxic T lymphocytes (CTLs) and modulation of the TME to support durable immune-mediated tumor clearance.

10.3 Types of toxicity of cancer nanovaccine

Acute versus chronic toxicity: Acute toxicity refers to adverse effects that emerge shortly after nanovaccine administration. Common manifestations include fever, diarrhea, nausea, lethargy [12], and allergic reactions [9]. These symptoms typically result from immediate immune activation or hypersensitivity [22]. In contrast, chronic toxicity evolves over prolonged periods and may include liver and spleen toxicity [16]. Such effects are particularly relevant when nanoparticles persist in the body or induce long-term immune modulation. Nanoparticles introduce the possibility of unpredictable adverse effects in cancer patients [23]. Beyond the well-known hazards linked to poor degradation, DNA damage, or metal-induced central nervous system toxicity, nanoformulations may also cause persistent, chronic, and often irreversible immune-related side effects, adding another layer of complexity to their utilization [23]. Therefore efficiently reducing nanotoxicity while preserving consistent antitumor benefits in patients treated with cytokine nanoformulations remains an ongoing significant challenge.

Local versus systemic toxicity: Local toxicity is confined to the site of injection and may present as pain, swelling, or subcutaneous induration [24]. It is often influenced by the formulation’s pH, excipients, or adjuvants. Systemic toxicity refers to the adverse effects caused by nanovaccine administration when using nanoparticles as carriers or adjuvants, that include fever, diarrhea, nausea, and tiredness [9]. The major toxicological pathways activated by nanoparticles in cells include oxidative stress, inflammation, and genotoxicity [25].

Nanovaccine safety profiles vary widely depending on both the nanomaterial and delivery strategy, often resulting in a combination of acute/chronic and local/systemic toxicities (Fig. 10.2). Following are the examples from specific nanoplatforms.

- **Lipid-based nanoparticles (LNPs) (e.g., mRNA cancer vaccines):** These systems, such as those used in COVID-19 vaccines, have shown effective delivery of nucleic acids. However, adverse effects include fatigue, pain at the injection




FIGURE 10.1 Mechanism of action of nanovaccines in cancer immunotherapy. This diagram illustrates the key steps in the immune activation process induced by nanovaccines for cancer treatment. Nanovaccines containing tumor-specific antigens and immunostimulatory adjuvants are administered via subcutaneous or intramuscular injection. These nanoparticles drain into the lymphatic system and accumulate in lymph nodes, where they are internalized by dendritic cells (DCs). Inside DCs, antigens are processed and presented on MHC molecules to activate naïve CD8⁺ and CD4⁺ T cells. CD8⁺ T cells differentiate into cytotoxic T lymphocytes (CTLs) targeting tumor cells, while CD4⁺ T cells mature and support effector functions. The immune response leads to tumor modulation and eradication. However, overactivation may result in potential toxicity such as cytokine storm or hypersensitivity reactions.




FIGURE 10.2 Types and mechanisms of nanovaccine-associated toxicity in cancer therapy. This figure illustrates the major classifications and mechanisms of nanovaccine-induced toxicity in cancer therapy. The top panel categorizes toxicity into acute, chronic, local, and systemic, detailing their interconnectedness, clinical manifestations, and target organs. Mechanistic pathways such as oxidative stress, inflammation, immune stimulation, and hypersensitivity are highlighted as key contributors to nanotoxicity. The lower panel describes examples from three major nanoplateforms, including lipid based, polymeric, and inorganic nanoparticles, and highlights their unique toxic effects, biological responses, and the risks associated with long term exposure or with biodegradation byproducts.

site, myalgia, narcolepsy, neurological side effects, anaphylaxis, immune activation, cytotoxicity, and nausea, while in PEGylated-lipids, PEG may cause allergic reactions [26].

- **Polymeric nanoparticles:** Composed of biodegradable materials like PLGA or chitosan, these carriers can degrade into acidic or reactive byproducts [27]. High doses may overwhelm cellular detoxification mechanisms, resulting in oxidative stress, inflammation, or cell death via apoptosis [28].
- **Inorganic nanoparticles (Gold, Silica, etc.):** These offer high stability and surface functionalization but are not easily metabolized. Studies have shown that gold nanoparticles can induce primary DNA damage, oxidative DNA damage, chromosomal damage, alterations in gene expression, and effects on epigenetic regulation [29], while silica particles can cause pulmonary inflammation and fibrosis upon inhalation [30].

To contextualize these toxicities within the broader design of nanovaccines, Table 10.1 summarizes key aspects of formulation strategies, their immunological advantages, and associated toxicological concerns. By mapping specific design features such as antigen delivery, personalization, and immune modulation to their benefits and risks, this table provides a critical framework for understanding the complex balance between efficacy and safety in nanovaccine development.

10.4 Immunogenicity and autoimmune reactions

Nanovaccines are designed to robustly stimulate the immune system to recognize and eliminate cancer cells. However, this potent immunogenicity can sometimes lead to unintended immune consequences, including immunotoxicity and adverse inflammatory responses [36]. This section outlines the key mechanisms by which nanovaccines may trigger such immune-related complications and highlights the importance of long-term safety evaluation. Despite their therapeutic promise, nanovaccines may induce immunological and organ-specific toxicities if not properly engineered or dosed. Fig. 10.3 summarizes these adverse effects, including immune-related complications such as cytokine storm [37], molecular mimicry [38], and immunotoxicity [36], as well as organ-specific toxicities in the liver, kidneys, lungs, and brain due to nanoparticle accumulation and systemic exposure.

Heightened immunogenicity and aberrant immune activation: While immune activation is critical for vaccine efficacy, excessive or poorly regulated immune stimulation can be detrimental. Nanovaccines often incorporate adjuvants and surface ligands that amplify antigen presentation and immune cell recruitment [17]. In some cases, these stimuli may provoke uncontrolled immune responses, leading to systemic inflammation and adverse immune-mediated effects [16]. The activation of DCs, macrophages, and T cells must be carefully modulated to avoid hyperresponsiveness.

Molecular mimicry and cross-reactivity with host tissues: One of the major risks associated with nanovaccine-induced autoimmunity is molecular mimicry [38]. If the antigens presented by the nanovaccine share structural similarities with endogenous proteins, the immune system may inadvertently attack healthy tissues. This cross-reactivity can result in the development of autoimmune diseases such as type 1 diabetes, thyroiditis, or lupus-like syndromes. The risk is heightened when targeting tumor-associated antigens that are also expressed, albeit at lower levels, in normal tissues.

Autoantibody production and immune dysregulation: In some cases, exposure to nanovaccines has been linked to the production of autoantibodies, which are antibodies that mistakenly attack the body's own proteins. These autoantibodies may play a role in various disorders, including vasculitis and autoimmune encephalitis. Moreover, dysregulation of T regulatory cells (Tregs) and loss of peripheral tolerance mechanisms may exacerbate these autoimmune processes. The balance between effector and regulatory immune cells is therefore crucial in maintaining immune homeostasis [39].

10.5 Organ-specific toxicities

Liver and kidney toxicity: Some LNPs induce mitochondrial dysfunction and oxidative stress in hepatocytes [40]. High-dose aluminum nanoparticles (ALNP) exhibit renal tubular necrosis, glomerular swelling, intertubular hemorrhage, and hepatocyte degeneration [41].

Pulmonary effects (e.g., Inflammation, Fibrosis): Nanoparticles that reach the lungs via systemic circulation or inhalation may disrupt alveolar integrity [42] and induce inflammation. In rodents, inhalation of silver nanoparticles has resulted in increased silver in the lungs, lymph nodes, liver, kidney, spleen, ovaries, and testes [43]. Acute effects in humans of the inhalation of silver include lung failure that involves increased heart rate and decreased arterial blood oxygen pressure [43]. Argyria, a blue-gray discoloration of skin due to deposited silver, was observed after pulmonary

TABLE 10.1 Comparative overview of nanovaccine design strategies and associated toxicities.

Aspect	Mechanism/design feature	Benefits	Potential toxicities/concerns	Examples	References
Antigen delivery	Encapsulation or surface attachment	Protects antigens; promotes uptake by APCs	May trigger unintended immune activation	Lipid/polymer nanoparticles	Wang et al. [31]
Personalization	Incorporation of neoantigens	High specificity; low autoimmunity risk	Requires sequencing infrastructure	mRNA-loaded lipid nanoparticles	Cao and Xia [32]
Immune modulation	Co-delivery of adjuvants, checkpoint inhibitors	Enhances immune activation	Systemic inflammation, cytokine storms	TLR agonists like CpG, MPLA	Nie et al. [33]
TME reprogramming	Delivery of siRNAs, modulators of immune cells	Converts “cold” to “hot” tumors	Off-target gene silencing	siRNA for PD-L1 silencing	Yi et al. [34]
Carrier material	Lipids, metals, polymers	Enables tunable delivery and release	ROS generation, organ accumulation	Iron oxide, gold nanoparticles	Ramos-Pan et al. [29]
Endosomal escape	Ionizable lipids	Promotes cytosolic antigen access	Lipid peroxidation, innate immune activation	Ionizable LNPs	Zelkoski et al. [35]
Stability enhancer	PEGylation	Prolonged circulation	Anti-PEG antibodies, hypersensitivity	PEGylated LNPs	Cao et al. [26]
Inflammatory risk	Systemic cytokine activation	Strong immune priming	Cytokine storm, multiorgan dysfunction	mRNA nanovaccines in preclinical models	Cao et al. [26]




FIGURE 10.3 Immunological and organ-specific toxicities induced by nanovaccines. This diagram presents the immunological and organ-specific toxicities associated with nanovaccines. On the left, immune system activation is shown to occasionally result in exaggerated responses such as cytokine storms, molecular mimicry, and autoantibody production, which can target healthy tissues like the pancreas, thyroid, and joints, potentially leading to chronic inflammation and autoimmune disorders. On the right, systemic distribution of nanoparticles to major organs such as the liver, kidneys, lungs, and brain is depicted. Accumulation in these organs may cause oxidative stress, nephrotoxicity, pulmonary inflammation, and neuroinflammation, highlighting the importance of safety profiling in nanovaccine development.

exposure in three individuals [43]. In rats, CeO_2 nanoparticles penetrate the alveolar space and show lung tissue inflammation with increasing severity post-exposure [44].

Neurotoxicity: Nanoparticles can also raise concerns about neurotoxicity [21]. Nanomaterials may induce neurotoxicity through multiple mechanisms, including oxidative stress, DNA damage, lysosomal dysfunction, inflammatory cascade, apoptosis, genotoxicity, and ultimately necrosis of neuronal cells [45].

10.6 Factors influencing nanovaccine toxicity

Particle size, surface charge, shape: Nanoparticle size influences tissue penetration, cellular uptake, and clearance rates. Smaller particles (<100 nm) can penetrate tissues more efficiently but may accumulate in sensitive organs [46]. Surface charge affects protein corona formation and cell membrane interactions; positively charged particles tend to have higher cellular uptake but also greater cytotoxicity [47]. Particle shape influences circulation dynamics—spherical particles tend to circulate longer, while rod-shaped or irregular particles may be more rapidly cleared [48].

Route of administration (IV, subcutaneous, intramuscular): Different administration routes result in distinct biodistribution profiles [49]. Intravenous delivery ensures systemic distribution but increases the risk of systemic toxicity [50]. Subcutaneous and intramuscular routes allow depot formation and slower release but may cause localized inflammation or granuloma formation [51,52]. The chosen route must align with therapeutic goals and toxicity risk profiles.

Dose and frequency: Nanovaccine toxicity is dose-dependent [52]. Higher doses can overwhelm detoxification pathways, while repeated doses may result in bioaccumulation and immune sensitization [53]. Dosing intervals must be optimized to minimize toxicity while maintaining therapeutic efficacy. Cumulative exposure should be carefully monitored in clinical settings.

Tumour microenvironment interactions: The TME presents unique challenges, including hypoxia, acidic pH, and immunosuppressive signaling [54]. Nanoparticles may behave differently within the TME compared to healthy tissue [55]. For example, acidic pH may trigger premature payload release [56], while tumor-associated macrophages may sequester nanoparticles and alter their biodistribution [57]. These interactions can modulate both efficacy and toxicity.

10.7 Types of nanoparticles and their associated toxicities in cancer nanovaccines

The rapid development of nanovaccine technologies has introduced various nanoparticle types, each with specific therapeutic advantages and toxicity risks.

10.7.1 Nucleic acid-based platforms (DNA/RNA)

Nucleic acid-based nanovaccines particularly DNA and RNA formulations represent a transformative approach to cancer immunotherapy by enabling endogenous antigen production. These vaccines activate both cytotoxic (CD8⁺) and helper (CD4⁺) T cells through engagement of MHC class I and II pathways, thereby mimicking natural infection-induced immunity [11]. However, their delivery systems introduce important toxicological challenges. DNA-based nanovaccines, which require nuclear localization for transcription, suffer from low efficiency in non-dividing tumor cells. Moreover, the long persistence of plasmid DNA raises concerns over insertional mutagenesis and potential oncogenic risk. Although nonviral DNA nanoparticles are generally considered safer than viral vectors, their effects on epigenetic regulation and genomic stability remain incompletely understood. RNA-based nanovaccines notably mRNA vaccines, avoid nuclear entry but are inherently unstable. Their encapsulation in LNPs is critical for protection from degradation, but LNPs are known to induce systemic immune activation. Toxicity includes elevation of pro-inflammatory cytokines (e.g., IL-6), complement activation, and rare cases of myocarditis or laryngeal edema [11]. Additionally, RNA vaccines depend on strict cold-chain logistics, complicating deployment and increasing the risk of degradation and inconsistent dosing.

10.7.2 Antigen-based nanovaccines

Antigen-based nanovaccines deliver predefined tumor antigens directly, offering greater stability and ease of storage compared to nucleic acid-based platforms [11]. However, their immunogenic profiles are often less robust and may require adjuvants or repeated dosing. Fixed antigen content can also limit adaptability to tumor evolution, reducing efficacy in heterogeneous cancers. From a toxicity standpoint, antigen-based nanovaccines may cause local inflammatory reactions at the injection site, especially when combined with potent adjuvants. Their ability to trigger lasting memory responses is variable, and overuse could lead to immunological exhaustion or unwanted tissue reactivity.

10.7.3 Tumor-derived extracellular vesicles

Recent innovations have led to the engineering of tumor-derived EVs (tEVs) into multifunctional nanovaccines. These vesicles naturally incorporate tumor antigens and can be modified to act as self-adjuncting carriers. Notably, some platforms utilize mitochondria-targeted sonosensitizer molecules with aggregation-induced emission (AIE) characteristics, which have shown potent antitumor prophylactic effects in preclinical models [3]. While promising, tEV-based nanovaccines may raise safety concerns related to autoimmunity or the unintended promotion of tumor signaling pathways. The inclusion of endogenous tumor-derived proteins could also pose risks of tolerogenic responses or immune deviation. Furthermore, their biodistribution and clearance remain poorly understood, necessitating comprehensive pharmacokinetic studies [58].

10.7.4 Lipid-based nanoparticles and liposomes

LNPs, including liposomes, are among the most widely used delivery vehicles in cancer nanovaccine platforms [59]. They offer high biocompatibility and efficient encapsulation of nucleic acids or antigens. However, they are not devoid of toxicity. Liposomes, due to their bilayer structure, can become destabilized *in vivo*, leading to premature drug or antigen release [60]. Moreover, they can activate the complement cascade, triggering complement activation-related pseudoallergy (CARPA), which manifests as hypersensitivity reactions ranging from mild rashes to severe anaphylaxis [61]. LNPs used in mRNA vaccines have been implicated in cytokine release and innate immune activation. The use of ionizable lipids, crucial for endosomal escape, can cause mitochondrial damage, lipid peroxidation, and inflammation, especially when they interact with pattern recognition receptors (PRRs) [31,36]. Additionally, the presence of polyethylene glycol (PEG) on the surface of LNPs may provoke anti-PEG antibodies [62], potentially resulting in reduced efficacy and hypersensitivity reactions over repeated doses.

10.7.5 Polymeric nanoparticles

Polymeric nanoparticles, particularly those formulated from poly(lactic-co-glycolic acid) (PLGA), are favored for their controlled degradation and tunable release properties [63]. These systems are generally considered biocompatible and

have received regulatory approval for various drug delivery applications. However, the degradation rate and byproducts of vaccines can influence immunogenicity and toxicity [64]. Accumulation of acidic monomers may disrupt local tissue pH, provoke inflammatory responses, or impair antigen stability. Non-biodegradable polymers carry greater toxicity risks, including tissue accumulation, long-term oxidative stress, inflammation, and fibrotic responses [36,65]. Careful material selection and dosing regimens are required to mitigate these effects.

10.7.6 Inorganic nanoparticles

Inorganic nanoparticles, including gold, silica, and iron oxide offer unique advantages such as intrinsic imaging capability, magnetic responsiveness, and high surface area for functionalization. Nonetheless, their clinical translation in cancer nanovaccines remains limited due to significant toxicity concerns [21]. These particles tend to accumulate in reticuloendothelial organs like the liver and spleen and may persist for prolonged periods [66]. Their presence can disrupt cellular homeostasis, induce oxidative stress, and impair mitochondrial function. Studies have shown that metal ions released from these nanoparticles may also interfere with normal enzymatic activity, contributing to systemic toxicity [11]. Strategies such as coating, surface passivation, and controlled degradation are being explored to mitigate these risks.

10.7.7 Viral and DNA nanoparticles

Viral vector-based nanovaccines remain potent tools for delivering genetic material due to their high transduction efficiency. However, they come with substantial safety concerns [67]. Integration of viral DNA into the host genome poses the risk of insertional mutagenesis, which can trigger oncogenesis. Moreover, pre-existing immunity to viral vectors may limit effectiveness and exacerbate inflammatory responses. Non-viral DNA nanoparticles, although comparatively safer, are not free of risks. The potential for unintended genetic effects, epigenetic alterations, or immune sensitization requires thorough preclinical evaluation [68,69]. These risks are particularly relevant in the context of cancer, where immune tolerance and genomic instability are already prevalent.

As illustrated in Fig. 10.4, different nanoparticle platforms exhibit distinct physicochemical properties and toxicological profiles relevant to their use in cancer nanovaccines. Nucleic acid-based platforms (e.g., mRNA-LNPs) offer high immunogenicity but may trigger systemic inflammation or hypersensitivity reactions. Lipid-based systems are widely used due to biocompatibility, but can induce CARPA and mitochondrial stress. Polymeric nanoparticles allow controlled release but may generate inflammatory acidic byproducts. Inorganic materials, though advantageous for imaging and surface modification, face limitations due to oxidative stress and metal toxicity. tEVs and viral/DNA vectors raise additional safety questions related to immune modulation, autoimmunity, or genomic integration.

10.8 Combination therapies and clinical validation

Combining nanovaccines with immunotherapies or conventional modalities offers synergistic benefits. ICIs (e.g., anti-PD-1/PD-L1) can reverse T cell exhaustion, amplifying vaccine-induced immune responses. Concurrently, chemotherapy or radiotherapy can induce immunogenic cell death, increase tumor antigen availability, and enhance vaccine efficacy. Such combinations may also reduce individual drug dosages, thereby limiting cumulative toxicity and expanding the therapeutic window. Early-phase clinical trials of nanovaccines, including liposomal and mRNA-based LNP formulations, have shown encouraging safety profiles. Reported adverse events are typically mild and transient, such as localized pain, flu-like symptoms, and low-grade fever. For instance liposomal nanovaccines maintain efficient antigen delivery while minimizing off-target immunogenicity. PLGA-based platforms strike a favorable balance between sustained antigen release and biocompatibility. Real-world data reinforce these findings, with most adverse effects being manageable and immune-related (e.g., fatigue, chills, myalgia). However, transient elevations in liver enzymes observed with iron oxide nanoparticles highlight the need for continued hepatic monitoring. These outcomes underscore the importance of preclinical toxicology screening and post-treatment surveillance in clinical settings.

10.9 Progress, challenges, and future directions

Animal studies demonstrate nanovaccine-induced tumor regression, enhanced DC activation, and CTL priming in models of melanoma, breast cancer, and glioblastoma. Multifunctional nanoparticles co-delivering antigens and immunostimulatory molecules can remodel the TME, shifting it from immunosuppressive to immunogenic. Clinically, personalized mRNA nanovaccines such as BioNTech and Roche's BNT122 and Moderna's mRNA-4157 have shown potent neoantigen-specific T cell responses. In metastatic melanoma, these vaccines have demonstrated improved recurrence-




FIGURE 10.4 Comparative overview of nanoparticle types used in cancer nanovaccines and their associated toxicities. This infographic presents a comparative chart of key nanoparticle platforms employed in cancer nanovaccines, detailing their composition, major therapeutic advantages, and associated toxicological risks. Nanoparticle classes include nucleic acid-based, antigen-based, tumor-derived extracellular vesicles (TEVs), lipid-based, polymeric, inorganic, and viral/DNA-based systems. The figure highlights both clinical readiness and major safety concerns, such as systemic inflammation, CARPA, oxidative stress, mitochondrial damage, insertional mutagenesis, and poor biodistribution. *CARPA*, Complement activation-related pseudoallergy.

free survival, especially when combined with checkpoint inhibitors like pembrolizumab. These results highlight the potential of combining precision immunotherapy with nanotechnology for enhanced clinical outcomes.

Despite significant progress, several challenges hinder the widespread clinical translation of nanovaccines, including clinical trial design and biosafety of nanomaterials [23]. Manufacturing complexity and batch variability affect particle size, surface charge, and antigen loading consistency, all of which influence safety and efficacy. Regulatory frameworks for nanomedicine are still evolving, requiring harmonization and clear GMP compliance for large-scale production. Immune overactivation remains a serious concern, particularly in formulations with potent adjuvants or self-antigen cross-reactivity. Risks of cytokine release syndrome (CRS) and autoimmune reactions necessitate rigorous preclinical immune toxicity testing and careful clinical dosing strategies. Gradual immune priming and personalized dosing schedules may help mitigate these risks.

Looking forward, personalized nanovaccines designed using patient-specific neoantigen profiles offer an exciting avenue for precision oncology. The integration of genomic sequencing and artificial intelligence can improve epitope selection, reduce off-target toxicity, and enhance treatment response. Meanwhile, innovations in self-degrading nanoparticle systems and biocompatible materials continue to push the boundaries of safety and functionality. Together, these strategies form a comprehensive roadmap toward the safe, effective, and scalable application of nanovaccines in cancer immunotherapy.

10.10 Conclusion

The rapid evolution of nanovaccines has opened new frontiers in cancer immunotherapy by enabling precise antigen delivery, potent immune activation, and tumor-specific targeting. However, these advancements are paralleled by complex safety challenges. This chapter has outlined the multifaceted toxicities associated with nanovaccines ranging from acute and local injection site reactions to chronic and systemic effects such as hepatic stress, inflammatory syndromes, and

immune overactivation. These adverse events are shaped by the physicochemical properties of nanoparticles, their route of administration, and the immunological context of the host.

Preclinical and clinical data underscore the dual-edged nature of nanovaccines: while offering enhanced efficacy through antigen presentation and immune stimulation, they can also provoke unintended toxicities through oxidative stress, cytokine storms, or off-target effects. Notably, the diversity of nanoplatforms including lipid-based, polymeric, and inorganic systems results in distinct risk–benefit profiles, underscoring the need for tailored design strategies and rigorous safety assessments.

Mitigating toxicity requires a systems-level approach involving rational material selection, surface modifications (e.g., PEGylation), controlled-release mechanisms, and tumor-targeting technologies. Personalized vaccine design, informed by genomic profiling and machine learning, represents a promising strategy to enhance specificity while minimizing immunotoxicity. Moreover, combination therapies with checkpoint inhibitors or traditional cancer treatments can boost efficacy without proportionally increasing systemic burden if dose-optimized and clinically validated.

Despite encouraging early-phase trials, key translational barriers persist, including manufacturing consistency, regulatory standardization, and immune unpredictability. Addressing these issues will demand rigorous preclinical models, robust clinical monitoring, and interdisciplinary collaboration. In conclusion, while the side effects and toxicity of nanovaccines remain a critical concern, they are not insurmountable. By integrating advances in nanotechnology, immunology, and systems biology, the field is well-positioned to deliver safer, more effective cancer vaccines. Continued innovation and vigilance will be essential to realize the full therapeutic potential of nanovaccines while safeguarding patient health in both early trials and eventual clinical practice.

References

- [1] WHO. (2025). Cancer. *World Health Organisation*, February.
- [2] Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines. *Vaccines* 2023;11(11):1633. Available from <https://doi.org/10.3390/vaccines11111633>.
- [3] Chen Y, Bao Y, Wang Y, Liu J, Zheng W, Chen P, et al. Alkyl chain engineering of ionic AIE molecules for developing superior self-adjuvanted nanovaccines in cancer immunotherapy. *Chemical Engineering Journal* 2025;506:159979. Available from <https://doi.org/10.1016/j.cej.2025.159979>.
- [4] Delgado-Almenta V, Blaya-Cánovas JL, Calahorra J, López-Tejada A, Griñán-Lisón C, Granados-Principal S. Cancer vaccines and beyond: the transformative role of nanotechnology in immunotherapy. *Pharmaceutics* 2025;17(2):1–40. Available from <https://doi.org/10.3390/pharmaceutics17020216>.
- [5] He J, Ding X, Zhao J, Zeng J, Zhou Y, Xiao W, et al. A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus. *Journal of Nanobiotechnology* 2024;22(1):738. Available from <https://doi.org/10.1186/s12951-024-03031-0>.
- [6] Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q, et al. Personalized nanovaccines for treating solid cancer metastases. *Journal of Hematology and Oncology* 2024;17(1). Available from <https://doi.org/10.1186/s13045-024-01628-4>.
- [7] Chen C, Xu Y, Meng H, Bao H, Hu Y, Li C, et al. Nano-oncologic vaccine for boosting cancer immunotherapy: the horizons in cancer treatment. *Nanomaterials* 2025;15:122. Available from <https://doi.org/10.3390/nano15020122>.
- [8] Li Y, Xu Y, Su W, Xu J, Ye Z, Wang Z, et al. Exploring the immuno-nano nexus: a paradigm shift in tumor vaccines. *Biomedicine and Pharmacotherapy* 2025;184:117897. Available from <https://doi.org/10.1016/j.biopha.2025.117897>.
- [9] Gurunathan S, Thangaraj P, Wang L, Cao Q, Kim JH. Nanovaccines: an effective therapeutic approach for cancer therapy. *Biomedicine and Pharmacotherapy* 2024;170:115992. Available from <https://doi.org/10.1016/j.biopha.2023.115992>.
- [10] Huang X, Zhu X, Yang H, Li Q, Gai L, Sui X, et al. Nanomaterial delivery vehicles for the development of neoantigen tumor vaccines for personalized treatment. *Molecules (Basel, Switzerland)* 2024;29(7):1–25. Available from <https://doi.org/10.3390/molecules29071462>.
- [11] Lin Y, Lin P, Xu R, Chen X, Lu Y, Zheng J, et al. Nanovaccines empowering CD8+ T cells: a precision strategy to enhance cancer immunotherapy. *Theranostics* 2025;15(7):3098–121. Available from <https://doi.org/10.7150/thno.107856>.
- [12] Yuan X, Xu T, Hussain M, Liu B, Zhu J. Recent advances of nanovaccines on cancer theranostics. *Frontiers in Nanotechnology* 2025;7:1521131. Available from <https://doi.org/10.3389/fnano.2025.1521131>.
- [13] Li Y, Li S, Jiang Z, Tan K, Meng Y, Zhang D, et al. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions. *Journal of Nanobiotechnology* 2023;21(1):212. Available from <https://doi.org/10.1186/s12951-023-01977-1>.
- [14] Zaccariotto Gde C, Bistaffa MJ, Zapata AMM, Rodero C, Coelho F, Quitiba JVB, et al. Cancer nanovaccines: mechanisms, design principles, and clinical translation. *ACS Nano* 2025;19:16204–23. Available from <https://doi.org/10.1021/acsnano.4c15765>.
- [15] Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. *Signal Transduction and Targeted Therapy* 2024;9:68. Available from <https://doi.org/10.1038/s41392-024-01765-9>.
- [16] Wang Y, Liu C, Fang C, Peng Q, Qin W, Yan X, et al. Engineered cancer nanovaccines: a new frontier in cancer therapy. *Nano-Micro Letters* 2025;17(1):30. Available from <https://doi.org/10.1007/s40820-024-01533-y>.
- [17] Priyanka, Abusalah MAH, Chopra H, Sharma A, Mustafa SA, Choudhary OP, et al. Nanovaccines: a game changing approach in the fight against infectious diseases. *Biomedicine and Pharmacotherapy* 2023;167:115597. Available from <https://doi.org/10.1016/j.biopha.2023.115597>.

- [18] Saleh M, El-Moghazy A, Elgohary AH, Saber WEIA, Helmy YA. Revolutionizing nanovaccines: a new era of immunization. *Vaccines* 2025;13(2):126. Available from <https://doi.org/10.3390/vaccines13020126>.
- [19] Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. *Signal Transduction and Targeted Therapy* 2023;8:283. Available from <https://doi.org/10.1038/s41392-023-01557-7>.
- [20] Liao Z, Huang J, Lo PC, Lovell JF, Jin H, Yang K. Self-adjuvanting cancer nanovaccines. *Journal of Nanobiotechnology* 2022;20:345. Available from <https://doi.org/10.1186/s12951-022-01545-z>.
- [21] Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer nanovaccines: nanomaterials and clinical perspectives. *Small (Weinheim an der Bergstrasse, Germany)* 2024;20(35):e2401631. Available from <https://doi.org/10.1002/sml.202401631>.
- [22] Ahmad S, Idris RAM, Wan Hanaffi WN, Perumal K, Boer JC, Plebanski M, et al. Cancer nanomedicine and immune system—interactions and challenges. *Frontiers in Nanotechnology* 2021;3:1–9. Available from <https://doi.org/10.3389/fnano.2021.681305>.
- [23] Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges. *Molecular Cancer* 2025;24:26. Available from <https://doi.org/10.1186/s12943-024-02214-5>.
- [24] Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, et al. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer. *Advanced Science* 2023;10(1):e2203298. Available from <https://doi.org/10.1002/advs.202203298>.
- [25] Mortimer GM, Minchin RF. Nanotoxicology and nanovaccines. *Micro- and Nanotechnology in Vaccine Development*. Elsevier Inc; 2017. Available from <https://doi.org/10.1016/B978-0-323-39981-4.00020-8>.
- [26] Cao LM, Yu YF, Li ZZ, Zhong NN, Wang GR, Xiao Y, et al. Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions. *Journal of Nanobiotechnology* 2024;22(308):1–14. Available from <https://doi.org/10.1186/s12951-024-02590-6>.
- [27] Hussain M, Khan SM, Shafiq M, Abbas N. A review on PLA-based biodegradable materials for biomedical applications. *Giant* 2024;18:100261. Available from <https://doi.org/10.1016/j.giant.2024.100261>.
- [28] Kumah EA, Fopa RD, Harati S, Boadu P, Zohoori FV, Pak T. Human and environmental impacts of nanoparticles: a scoping review of the current literature. *BMC Public Health* 2023;23:1059. Available from <https://doi.org/10.1186/s12889-023-15958-4>.
- [29] Ramos-Pan L, Touzani A, Fernández-Bertólez N, Fraga S, Laffon B, Valdiglesias V. Impact of gold nanoparticle exposure on genetic material. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis* 2024;900:503827. Available from <https://doi.org/10.1016/j.mrgentox.2024.503827>.
- [30] Tian J, Song D, Peng Y, Zhang J, Ma L, Chen Z, et al. Silica-induced macrophage pyroptosis propels pulmonary fibrosis through coordinated activation of relaxin and osteoclast differentiation signaling to reprogram fibroblasts. *Ecotoxicology and Environmental Safety* 2024;273:116106. Available from <https://doi.org/10.1016/j.ecoenv.2024.116106>.
- [31] Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, et al. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. *Vaccines* 2024;12:1148. Available from <https://doi.org/10.3390/vaccines12101148>.
- [32] Cao W, Xia T. mRNA lipid nanoparticles induce immune tolerance to treat human diseases. *Medical Review* 2023;3(2):180–3. Available from <https://doi.org/10.1515/mr-2023-0008>.
- [33] Nie J, Zhou L, Tian W, Liu X, Yang L, Yang X, et al. Deep insight into cytokine storm: from pathogenesis to treatment. *Signal Transduction and Targeted Therapy* 2025;10:112. Available from <https://doi.org/10.1038/s41392-025-02178-y>.
- [34] Yi Y, Yu M, Feng C, Hao H, Zeng W, Lin C, et al. Transforming “cold” tumors into “hot” ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy. *Matter* 2022;5(7):2285–305. Available from <https://doi.org/10.1016/j.matt.2022.04.032>.
- [35] Zelkoski AE, Lu Z, Sukumar G, Dalgard C, Said H, Alameh MG, et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4. *Npj Vaccines* 2025;10:73. Available from <https://doi.org/10.1038/s41541-025-01124-x>.
- [36] Pondman K, Le Gac S, Kishore U. Nanoparticle-induced immune response: health risk versus treatment opportunity? *Immunobiology* 2023;228:152317. Available from <https://doi.org/10.1016/j.imbio.2022.152317>.
- [37] Awaya T, Hara H, Moroi M. Cytokine storms and anaphylaxis following COVID-19 mRNA-LNP vaccination: mechanisms and therapeutic approaches. *Diseases* 2024;12:231. Available from <https://doi.org/10.3390/diseases12100231>.
- [38] Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, et al. Molecular mimicry and cancer vaccine development. *Molecular Cancer* 2023;22(75):1–12. Available from <https://doi.org/10.1186/s12943-023-01776-0>.
- [39] Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. *Acta Biomaterialia* 2020;108(21):1.
- [40] Gao C, Wang M, Zheng Y, Zhang L, He J, Liu B, et al. Hepatotoxicity of nanomaterials: from mechanism to therapeutic strategy. *Nanotechnology Reviews* 2024;13:20240074. Available from <https://doi.org/10.1515/ntrev-2024-0074>.
- [41] Younis MAH, Radhi MM, Hussein BF. Effects of different vaccines and aluminum nanoparticles (ALNPs) on liver and kidney of rabbits. *Galen Medical Journal* 2025;14:e3677. Available from <https://doi.org/10.31661/gmj.v14i.3677>.
- [42] Miller MR, Raftis JB, Langrish JP, McLean SG, Samutrtai P, Connell SP, et al. Inhaled nanoparticles accumulate at sites of vascular disease. *ACS Nano* 2017;11(5):4542–52. Available from <https://doi.org/10.1021/acsnano.6b08551>.
- [43] Hadrup N, Sharma AK, Loeschner K, Jacobsen NR. Pulmonary toxicity of silver vapours, nanoparticles and fine dusts: a review. *Regulatory Toxicology and Pharmacology* 2020;115:104690. Available from <https://doi.org/10.1016/j.yrtph.2020.104690>.
- [44] Schwotzer D, Ernst H, Schaudien D, Kock H, Pohlmann G, Dasenbrock C, et al. Effects from a 90-day inhalation toxicity study with cerium oxide and barium sulfate nanoparticles in rats. *Particle and Fibre Toxicology* 2017;14(23):1–20. Available from <https://doi.org/10.1186/s12989-017-0204-6>.

- [45] Hussain Z, Thu HE, Elsayed I, Abourehab MAS, Khan S, Sohail M, et al. Nano-scaled materials may induce severe neurotoxicity upon chronic exposure to brain tissues: a critical appraisal and recent updates on predisposing factors, underlying mechanism, and future prospects. *Journal of Controlled Release* 2020;328:873–94. Available from <https://doi.org/10.1016/j.jconrel.2020.10.053>.
- [46] Havelikar U, Ghorpade KB, Kumar A, Patel A, Singh M, Banjare N, et al. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. *Discover Nano* 2024;19(165). Available from <https://doi.org/10.1186/s11671-024-04118-1>.
- [47] Barbalinardo M, Chiarini F, Teti G, Paganelli F, Mercadelli E, Bartoletti A, et al. Surface charge overrides protein corona formation in determining the cytotoxicity, cellular uptake, and biodistribution of silver nanoparticles. *ACS Applied Bio Materials* 2025. Available from <https://doi.org/10.1021/acsabm.5c00392>.
- [48] Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. *Polymers* 2023;15:1596. Available from <https://doi.org/10.3390/polym15071596>.
- [49] Wang L, Rao Y, Liu X, Sun L, Gong J, Zhang H, et al. Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. *Journal of Nanobiotechnology* 2021;19(56):1–16. Available from <https://doi.org/10.1186/s12951-021-00803-w>.
- [50] Dölen Y, Valente M, Tagit O, Jäger E, Van Dinther EAW, van Riessen NK, et al. Nanovaccine administration route is critical to obtain pertinent iNKT cell help for robust anti-tumor T and B cell responses. *OncoImmunology* 2020;9(1):e1738813. Available from <https://doi.org/10.1080/2162402X.2020.1738813>.
- [51] Jia H, Liu J, Shi M, Abbas M, Xing R, Yan X. Microneedle delivery systems for vaccines and immunotherapy. *Smart Molecules* 2025:e20240067. Available from <https://doi.org/10.1002/smo.20240067>.
- [52] Carmona-Ribeiro AM, Pérez-Betancourt Y. Emerging cationic nanovaccines. *Pharmaceutics* 2024;16:1362.
- [53] Ebrahim YY, Hegazy AA, Elsayed AG, Elnosary AN, Kaoud EA, Zaki NH, et al. Nano-vaccines: pioneering the future of immunization. *ERU Research Journal* 2025;4(2):2366–99. Available from <https://doi.org/10.21608/erurj.2024.292340.1153>.
- [54] Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, et al. Tumor microenvironment signaling and therapeutics in cancer progression. *Cancer Communications* 2023;43(5):525–61. Available from <https://doi.org/10.1002/cac2.12416>.
- [55] Huai Y, Hossen MN, Willhelm S, Bhattacharya R, Mukherjee P. Nanoparticle interactions with the tumor microenvironment. *Bioconjugate Chemistry* 2019;30(9):2247–63. Available from <https://doi.org/10.1021/acs.bioconjchem.9b00448.Nanoparticle>.
- [56] Cheng R, Wang S, Santos HA. Acid-labile chemical bonds-based nanoparticles for endosome escape and intracellular delivery. *Biomedical Technology* 2023;3:52–8. Available from <https://doi.org/10.1016/j.bmt.2023.01.001>.
- [57] Nguyen LNM, Ngo W, Lin ZP, Sindhvani S, MacMillan P, Mladjenovic SM, et al. The mechanisms of nanoparticle delivery to solid tumours. *Nature Reviews Bioengineering* 2024;2:201–13. Available from <https://doi.org/10.1038/s44222-024-00154-9>.
- [58] Wang Z, Chen H, Ming R, Wang W, Liu S, Jing Y, et al. A self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers. *Journal of Nanobiotechnology* 2025;23(150):1–13. Available from <https://doi.org/10.1186/s12951-025-03208-1>.
- [59] Fan S, Han H, Yan Z, Lu Y, He B, Zhang Q. Lipid-based nanoparticles for cancer immunotherapy. *Medical Review* 2023;3(3):230–69. Available from <https://doi.org/10.1515/mr-2023-0020>.
- [60] Chen J, Hu S, Sun M, Shi J, Zhang H, Yu H, et al. Recent advances and clinical translation of liposomal delivery systems in cancer therapy. *European Journal of Pharmaceutical Sciences* 2024;193:106688. Available from <https://doi.org/10.1016/j.ejps.2023.106688>.
- [61] Khalid MB, Frischmeyer-Guerrerio PA. The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis. *Journal of Allergy and Clinical Immunology: Global* 2023;2(1):1–13. Available from <https://doi.org/10.1016/j.jacig.2022.10.003>.
- [62] Kozma GT, Mészáros T, Berényi P, Facskó R, Patkó Z, Oláh CZ, et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG. *Vaccine* 2023;41(31):4561–70. Available from <https://doi.org/10.1016/j.vaccine.2023.06.009>.
- [63] Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, et al. Recent applications of PLGA in drug delivery systems. *Polymers* 2024;16(2606):1–25. Available from <https://doi.org/10.3390/polym16182606>.
- [64] Koirala P, Chen SPR, Boer JC, Khalil ZG, Deceneux C, Goodchild G, et al. Polymeric nanoparticles as a self-adjuvanting peptide vaccine delivery system: the role of shape. *Advanced Functional Materials* 2023;33(12):2209304. Available from <https://doi.org/10.1002/adfm.202209304>.
- [65] Kyriakides TR, Raj A, Tseng TH, Xiao H, Nguyen R, Mohammed FS, et al. Biocompatibility of nanomaterials and their immunological properties. *Biomedical Materials (Bristol)* 2021;16(4):1–49. Available from <https://doi.org/10.1088/1748-605X/abe5fa>.
- [66] Kumar M, Kulkarni P, Liu S, Chemuturi N, Shah DK. Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles. *Advanced Drug Delivery Reviews* 2023;194:114708. Available from <https://doi.org/10.1016/j.addr.2023.114708>.
- [67] Tang J, Amin MA, Campian JL. Past, present, and future of viral vector vaccine platforms: a comprehensive review. *Vaccines* 2025;13(524):1–20. Available from <https://doi.org/10.3390/vaccines13050524>.
- [68] Musolino E, Pagiatakis C, Serio S, Borgese M, Gamberoni F, Gornati R, et al. The Yin and Yang of epigenetics in the field of nanoparticles. *Nanoscale Advances* 2022;4:979–94. Available from <https://doi.org/10.1039/d1na00682g>.
- [69] Shukla RK, Badiye A, Vajpayee K, Kapoor N. Genotoxic potential of nanoparticles: structural and functional modifications in DNA. *Frontiers in Genetics* 2021;12:728250. Available from <https://doi.org/10.3389/fgene.2021.728250>.

This page intentionally left blank

Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments

Edited by Tuan Anh Nguyen, Bhupendra G. Prajapati, and Devesh U. Kapoor

Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments provides a balanced exploration of the dual roles of nanotechnologies in oncology. Structured in four parts, this book begins with the foundational knowledge of nanovaccines and nanomedicines, detailing their applications in cancer care and highlighting their precision in targeting cancer cells while reducing systemic toxicity.

Importantly, this book addresses potential drawbacks, discussing side effects and safety concerns associated with these innovations. The final section emphasizes ethical, regulatory, and safety challenges, underscoring the need for careful oversight as nanotechnologies advance.

For the academic audience, this book serves as a vital resource, offering insights that equip researchers and healthcare professionals to make informed decisions regarding clinical applications. Its focus on both the benefits and risks, alongside forward-looking perspectives, ensures that readers are well prepared for future developments in the field of nanomedicine and cancer therapy.

Key Features

- Provides an in-depth foundation on nanovaccines and nanomedicines, detailing their mechanisms, roles, and applications in cancer treatment
- Addresses both the advantages and potential side effects of nanovaccines and nanomedicines
- Emphasizes the ethical, safety, and regulatory aspects of nanotechnology in cancer therapy, offering valuable guidance for responsible usage and oversight in clinical settings

About the Editors

Tuan Anh Nguyen is a Senior Principal Research Scientist at the Institute for Tropical Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam.

Bhupendra G. Prajapati is a Professor (Research Cadre), Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India.

Devesh U. Kapoor is a Professor at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, India.



ACADEMIC PRESS

An imprint of Elsevier
shop.elsevier.com

ISBN 978-0-443-44579-8



9 780443 445798